Skip to content

US · ORIC · BIOTECHNOLOGY

ORIC Pharmaceuticals, Inc. (ORIC) intrinsic value and stock valuation

$7.36as of 2026-11-21 · Mkt cap 1.4B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

ORIC Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values ORIC with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ORIC’s statements →

ORIC Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology South San Francisco, CA 94080 oricpharma.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$0.00
20172025
Net income
-$-129.47M
20172025
Free cash flow
-$-114.08M
20172025
Total equity
$384.4M+5.8% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-143M-$-142.9M-$-110.78M-$-91.77M-$-78.87M
Net income-$-129.47M-$-127.85M-$-100.7M-$-89.12M-$-78.72M
EPSd-$-1.47M-$-1.83M-$-1.96M-$-2.25M-$-2.07M
Operating cash flow-$-113.37M-$-112.66M-$-85.69M-$-75.14M-$-59.54M
Capital expenditure-$-710K-$-1.19M-$-850K-$-2.08M-$-940K
Free cash flow-$-114.08M-$-113.85M-$-86.54M-$-77.22M-$-60.48M
Total assets$411M$274.1M$254.7M$250.4M$298.6M
Total debt$11.6M$3.18M$10.2M$12.1M$1.93M
Net debt-$-34.12M-$-56.22M-$-13.17M-$-54.74M-$-224.08M
Total equity$384.4M$243.1M$224.1M$222.4M$273M
Cash and short-term investments$281.5M$256M$208.2M$206.3M$237M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$1.22M$1.11M$1.03M$0.00$0.00
Gross profit-$-1.22M-$-1.11M-$-1.03M$0.00$0.00
Research and development expenses$109.8M$114.1M$85.2M$61.7M$56.9M
Selling, general and administrative expenses$33.2M$28.8M$25.6M$25.1M$22M
Other expenses-$-1.22M-$-1.11M-$-1.03M$5M$0.00
Operating expenses$141.8M$141.8M$109.8M$91.8M$78.9M
Cost and expenses$143M$142.9M$110.8M$91.8M$78.9M
Interest income$0.00$0.00$10.1M$2.65M$140K
Interest expense$0.00$0.00$0.00$2.65M$0.00
Depreciation and amortization$1.22M$1.11M$1.03M$970K$900K
Ebitda-$-128.25M-$-126.74M-$-99.67M-$-85.8M-$-77.82M
Operating income-$-143M-$-142.9M-$-110.78M-$-91.77M-$-78.87M
Total other income/expenses, net$13.5M$15.1M$10.1M$2.65M$160K
Income before tax-$-129.47M-$-127.85M-$-100.7M-$-89.12M-$-78.72M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-129.47M-$-127.85M-$-100.7M-$-89.12M-$-78.72M
Weighted average shares outstanding$87.8M$69.7M$51.5M$39.7M$38M
Weighted average diluted shares outstanding$87.8M$69.7M$51.5M$39.7M$38M
Balance sheet
20252024202320222021
Cash and short-term investments$281.5M$256M$208.2M$206.3M$237M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$288.5M$262.3M$212.6M$210.5M$240.5M
Property, plant and equipment, net$9.07M$2.92M$12M$14.3M$2.41M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$111.3M$0.00$27.3M$22.4M$43.4M
Total non-current assets$122.5M$11.9M$42.1M$39.9M$58.1M
Total assets$411M$274.1M$254.7M$250.4M$298.6M
Accounts payable$3.82M$1.55M$940K$1.32M$1.89M
Short-term debt$3.33M$3.18M$2.75M$2.66M$1.93M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$20.4M$24.9M$20.5M$15.4M$15.2M
Long-term debt$8.22M$0.00$7.46M$9.44M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$6.22M$6.17M$10.1M$12.6M$10.5M
Capital lease obligations$4.11M$3.18M$7.46M$9.44M$1.93M
Total liabilities$26.6M$31M$30.6M$28M$25.7M
Common stock$10K$10K$10K$10K$0.00
Retained earnings-$-692.24M-$-562.77M-$-434.93M-$-334.23M-$-245.11M
Accumulated other comprehensive income (loss)$790K$380K$260K-$-1.29M-$-100K
Total equity$384.4M$243.1M$224.1M$222.4M$273M
Total investments$346.6M$196.6M$212.2M$161.9M$54.4M
Total debt$11.6M$3.18M$10.2M$12.1M$1.93M
Net debt-$-34.12M-$-56.22M-$-13.17M-$-54.74M-$-224.08M
Cash flow statement
20252024202320222021
Net income-$-129.47M-$-127.85M-$-100.7M-$-89.12M-$-78.72M
Depreciation and amortization$1.22M$1.11M$1.03M$970K$900K
Stock-based compensation$0.00$20.2M$15.2M$14.5M$12.9M
Change in working capital-$-5.46M$1.97M$4.9M-$-450K$4.07M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-7.25M$1.82M$0.00-$-1.48M$2.93M
Net cash provided by operating activities-$-113.37M-$-112.66M-$-85.69M-$-75.14M-$-59.54M
Investments in property, plant and equipment-$-710K-$-1.19M-$-850K-$-2.08M-$-940K
Acquisitions, net$0.00$0.00$0.00$2.08M$1.38M
Net cash used for investing activities-$-148.03M$22.1M-$-43.4M-$-109.25M$158.4M
Common stock issued$247.7M$125M$85M$25M$50M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$247.7M$126.6M$85.7M$25.2M$49.1M
Net change in cash-$-13.74M$36M-$-43.43M-$-159.17M$148M
Cash at end of period$46.2M$59.9M$23.9M$67.3M$226.5M
Operating cash flow-$-113.37M-$-112.66M-$-85.69M-$-75.14M-$-59.54M
Capital expenditure-$-710K-$-1.19M-$-850K-$-2.08M-$-940K
Free cash flow-$-114.08M-$-113.85M-$-86.54M-$-77.22M-$-60.48M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About ORIC Pharmaceuticals, Inc.

        ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.

        CEO
        Jacob Chacko
        Employees
        104
        Beta
        1.01

        Explore

        Frequently asked questions

        What is the intrinsic value of ORIC Pharmaceuticals, Inc. (ORIC)?

        InvestorsCraft does not currently publish an intrinsic value for ORIC. How the IC value is calculated.

        Is ORIC undervalued?

        InvestorsCraft does not publish an undervaluation signal for ORIC at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.